STOCK TITAN

Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Cidara Therapeutics (NASDAQ: CDTX) announced it will host a virtual R&D day on May 22, 2025, from 10:00 to 11:30 AM ET to discuss CD388, their innovative long-acting antiviral drug designed for universal, once-per-flu season prevention of seasonal and pandemic influenza.

The event will feature key opinion leaders Dr. Fred Hayden from the University of Virginia School of Medicine and Dr. Rick Bright from the Pandemic Prevention Institute. Topics will include the 2024-2025 flu season review, updates on the ongoing Phase 2b NAVIGATE trial's statistical analysis plan, planned Phase 3 study design, commercial opportunities, and competitive landscape for CD388.

Cidara Therapeutics (NASDAQ: CDTX) ha annunciato che terrà una giornata virtuale di R&S il 22 maggio 2025, dalle 10:00 alle 11:30 ET, per discutere di CD388, il loro innovativo farmaco antivirale a lunga durata d'azione progettato per la prevenzione universale, una volta per stagione influenzale, dell'influenza stagionale e pandemica.

L'evento vedrà la partecipazione di importanti esperti come il Dr. Fred Hayden dell'Università della Virginia School of Medicine e il Dr. Rick Bright del Pandemic Prevention Institute. I temi trattati includeranno la revisione della stagione influenzale 2024-2025, aggiornamenti sul piano di analisi statistica in corso della fase 2b dello studio NAVIGATE, il design previsto per lo studio di fase 3, le opportunità commerciali e il panorama competitivo per CD388.

Cidara Therapeutics (NASDAQ: CDTX) anunció que realizará un día virtual de I+D el 22 de mayo de 2025, de 10:00 a 11:30 AM ET, para hablar sobre CD388, su innovador medicamento antiviral de acción prolongada diseñado para la prevención universal, una vez por temporada de gripe, de la influenza estacional y pandémica.

El evento contará con la participación de destacados expertos como el Dr. Fred Hayden de la Universidad de Virginia School of Medicine y el Dr. Rick Bright del Pandemic Prevention Institute. Los temas incluirán la revisión de la temporada de gripe 2024-2025, actualizaciones sobre el plan de análisis estadístico del ensayo en curso de fase 2b NAVIGATE, el diseño previsto del estudio de fase 3, oportunidades comerciales y el panorama competitivo para CD388.

Cidara Therapeutics (NASDAQ: CDTX)는 2025년 5월 22일 오전 10시부터 11시 30분(동부시간)까지 가상 연구개발(R&D) 데이를 개최하여 CD388에 대해 논의할 예정입니다. CD388은 계절성 및 팬데믹 인플루엔자에 대해 한 시즌에 한 번 투여하는 보편적인 예방을 위해 설계된 혁신적인 장기 작용 항바이러스제입니다.

이번 행사에는 버지니아 대학교 의과대학의 프레드 헤이든 박사와 팬데믹 예방 연구소의 릭 브라이트 박사 등 주요 의견 리더들이 참여합니다. 논의 주제는 2024-2025 독감 시즌 검토, 진행 중인 2b상 NAVIGATE 임상시험 통계 분석 계획 업데이트, 예정된 3상 시험 설계, 상업적 기회 및 CD388의 경쟁 환경을 포함합니다.

Cidara Therapeutics (NASDAQ : CDTX) a annoncé qu'elle organisera une journée virtuelle de R&D le 22 mai 2025, de 10h00 à 11h30 ET, pour discuter de CD388, leur médicament antiviral innovant à action prolongée conçu pour une prévention universelle, administrée une fois par saison grippale, contre la grippe saisonnière et pandémique.

L'événement accueillera des experts de renom tels que le Dr Fred Hayden de l'Université de Virginie School of Medicine et le Dr Rick Bright de l'Institut de Prévention des Pandémies. Les sujets abordés incluront le bilan de la saison grippale 2024-2025, les mises à jour sur le plan d'analyse statistique de l'essai de phase 2b NAVIGATE en cours, la conception prévue de l'étude de phase 3, les opportunités commerciales et le paysage concurrentiel pour CD388.

Cidara Therapeutics (NASDAQ: CDTX) gab bekannt, dass am 22. Mai 2025 von 10:00 bis 11:30 Uhr ET ein virtueller F&E-Tag stattfinden wird, um CD388 zu besprechen, ihr innovatives langwirksames antivirales Medikament, das für eine universelle, einmal pro Grippesaison stattfindende Prävention gegen saisonale und pandemische Influenza entwickelt wurde.

Die Veranstaltung wird von führenden Experten wie Dr. Fred Hayden von der University of Virginia School of Medicine und Dr. Rick Bright vom Pandemic Prevention Institute begleitet. Themenschwerpunkte sind der Rückblick auf die Grippesaison 2024-2025, Updates zum statistischen Analyseplan der laufenden Phase-2b-Studie NAVIGATE, das geplante Design der Phase-3-Studie, kommerzielle Chancen und das Wettbewerbsumfeld für CD388.

Positive
  • None.
Negative
  • None.

SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, click here.

The event will feature key opinion leaders (KOLs) Fred Hayden, MD, FACP (University of Virginia School of Medicine) and Rick Bright, PhD (Pandemic Prevention Institute, The Rockefeller Foundation), who will join company management to discuss CD388, Cidara's long-acting antiviral drug designed to revolutionize influenza protection as a potential universal, once-per-flu season preventative.

Key topics will include a review of the 2024-2025 influenza season in the northern hemisphere, the design and objectives of the Company’s ongoing Phase 2b NAVIGATE trial with updates on the anticipated statistical analysis plan to evaluate the Phase 2b efficacy results when available, current thoughts on the planned Phase 3 study design, a review of the commercial opportunity and competitive landscape for CD388, and the prospects for pandemic influenza.

A live question and answer session will follow the formal presentations.

About Frederick G. Hayden, MD, FACP
Frederick G. Hayden, MD, FACP, is a Stuart S. Richardson Professor Emeritus of Clinical Virology and Professor Emeritus of Medicine at the University of Virginia School of Medicine in Charlottesville, Virginia, USA. His principal research interests have been on respiratory viral infections with a particular focus on the development and application of antiviral agents for influenza, rhinovirus, and coronavirus infections. He has contributed to the development of seven influenza antivirals and two vaccines approved for clinical use in one or more countries. During the COVID-19 pandemic he collaborated with colleagues in China to conduct the first controlled trials of candidate antivirals in hospitalized patients and has served as a consultant to platform studies (UK CTAP, ACTIV, AGILE), academic groups, and industry regarding the selection of therapeutics for clinical trials. Dr. Hayden received his medical degree from Stanford University School of Medicine in 1973 and completed his clinical training in internal medicine and infectious diseases at Strong Memorial Hospital, University of Rochester, New York.

About Rick Bright, PhD
Rick Bright, PhD, is an international expert on pandemic preparedness and response. In his most recent role as the Chief Executive Officer of the Pandemic Prevention Institute (PPI) at The Rockefeller Foundation, Dr. Bright led the development of the Foundation’s pandemic data-to-action platform that integrates modern technology, data analytics and global partners to help the world detect, prevent, and mitigate pandemic threats to achieve containment as quickly as possible. Dr. Bright serves as an international subject matter expert in biodefense, emergency preparedness and response, pharmaceutical innovation, vaccine, drug and diagnostic development and served as an advisor to the Biden Administration, the Coalition for Epidemic Preparedness Innovations (CEPI) and the National Academies of Sciences, Engineering & Medicine Forum on Microbial Threats. Dr. Bright received a Ph.D. in Immunology and Molecular Pathogenesis from Emory University and a B.S. magna cum laude in Biology and Physical Sciences from Auburn University at Montgomery.

About CD388

CD388 is an investigational drug-Fc conjugate (DFC) comprised of multiple copies of a potent small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody. DFCs are not vaccines or monoclonal antibodies but are low molecular weight biologics which are designed to function as long-acting small molecule inhibitors. CD388 was designed to provide universal protection against all known strains of seasonal and pandemic influenza with the potential to provide season-long protection with a single subcutaneous or intramuscular administration. Importantly, because CD388 is not a vaccine, its activity is not reliant on an immune response and thereby is expected to be efficacious in individuals regardless of immune status. More information can be found at: https://www.cidara.com/cloudbreak/influenza/

About Cidara Therapeutics

Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of enrollment of its Phase 2b NAVIGATE trial in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “intends,” “believes,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to the potential benefits of and future plans for CD388, the expected timing for reporting top-line data from the Phase 2b NAVIGATE clinical trial, the potential impact of data from the Phase 2b NAVIGATE clinical trial, the design of a potential Phase 3 study, and the potential commercial opportunity for CD388. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s clinical trials and other risks related to clinical development, delays in action by regulatory authorities and other risks and uncertainties associated with Cidara’s business in general. These and other risks are identified under the caption “Risk Factors” in Cidara’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 and other filings subsequently made with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com


FAQ

What is the purpose of Cidara Therapeutics' (CDTX) R&D Day on May 22, 2025?

The R&D Day will discuss CD388, their long-acting antiviral drug designed as a potential universal, once-per-flu season preventative for seasonal and pandemic influenza, including updates on clinical trials and commercial opportunities.

Who are the key speakers at CDTX's May 2025 R&D Day?

The event will feature Dr. Fred Hayden from University of Virginia School of Medicine and Dr. Rick Bright from the Pandemic Prevention Institute, along with company management.

What is CD388 and what is its potential use?

CD388 is Cidara's long-acting antiviral drug designed to be a universal, once-per-flu season preventative treatment for both seasonal and pandemic influenza.

What clinical trial updates will be discussed at Cidara's R&D Day?

The event will discuss the Phase 2b NAVIGATE trial's statistical analysis plan and planned Phase 3 study design for CD388.
Cidara Theraptcs

NASDAQ:CDTX

CDTX Rankings

CDTX Latest News

CDTX Stock Data

246.17M
12.75M
1.38%
69.43%
2.17%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO